[Telaprevir in treatment-naïve patients with HCV monoinfection].
Chronic hepatitis due to the hepatitis C virus (HCV) infection affects nearly 180 million people worldwide. This infection is curable. Until 1 year ago, the only treatment for genotype 1 HCV was the combination of pegylated interferon and ribavirin, which was only moderately effective (40-50%). The introduction of new antiviral agents, such as telaprevir, represents a change of paradigm and has revolutionized the treatment of this infection. This drug has increased the likelihood of viral response (to 80%) and has allowed treatment length to be shortened in more than 50% of patients. New stopping rules have been developed to avoid the development of resistances. Finally, special attention should be paid to potentially serious adverse effects, particularly anemia and cutaneous alterations.
Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, España. Electronic address: jcabezas@humv.es.
Joaquín
J
Cabezas
Javier
J
Crespo
Josefina
J
Selmo
José
J
Luis Calleja
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications; D016174:Hepacivirus / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000627:therapeutic use; D055815:Young Adult
D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; D007372:Interferons
Agentes antivirales directos; Direct antiviral agents; Hepatitis C; Inhibidores de la proteasa; Protease inhibitors; Telaprevir